Mylan Still Mulling Revance's Botox Biosimilar

Firms Are Still In Discussions Despite Passing 30 April Deadline

 
• By Dave Wallace

Revance says it is still in discussions with Mylan on whether or not the pair will proceed with their collaboration on a biosimilar version of Botox, despite an extended deadline for a commitment on the deal having passed on 30 April.

Girl_Botox_Injection
Revance is still waiting for a decision from Mylan despite passing a key date • Source: Shutterstock

More from Biosimilars

More from Products